Search results
Combined flu and Covid vaccine from Moderna shows positive trial results
PA Media: Science via Yahoo News· 7 days agoThe randomised controlled trial involved two groups of about 4,000 people each, with the first group...
FDA reverses course, calls for vaccines for fall 2024 to target newer COVID-19 strain
Scripps News via AOL· 3 days agoThe FDA is reversing course on its COVID vaccine guidance: Rather than having a vaccine that targets...
FDA reverses course, calls for vaccines for fall 2024 to target newer COVID-19 strain
AOL· 3 days agoThe Food and Drug Administration provided updated guidance for COVID-19 vaccine makers, calling for...
2-in-1 shot for flu and COVID shows promise in advanced trial
Live Science via Yahoo News· 7 days agoThe new vaccine builds upon the Nobel Prize-winning technology used to develop the first...diseases,...
Another COVID vaccine? Yes, and here’s why
San Jose Mercury News· 6 days agoThis fall, prepare for the latest round of COVID vaccine Whac-a-Mole. Protection against both infection and severe illness is waning. “Effectiveness has...
FDA to vaccinemakers: Updated COVID shots should target KP.2 variant
Becker’s Hospital Review· 3 days agoThe FDA is now advising manufacturers to develop the 2024-2025 COVID-19 vaccines using the KP.2 strain for the formula, the agency announced ...
2-in-1 shot for flu and COVID shows promise in advanced trial
LiveScience· 7 days agoAn experimental two-in-one vaccine triggered strong immune responses against both the flu and SARS-CoV-2, the virus behind COVID ...
FDA recommends COVID jab manufacturers update formulas to combat new strain
BizPac Review· 2 days agoA new strain of COVID has prompted recommendations for vaccine companies to update their formulas in anticipation of cases in the fall ...
Combo COVID/flu vaccine elicits higher immune response in trial
United Press International via Yahoo News· 7 days agoAn experimental vaccine that could offer one-stop prevention for both COVID-19 and influenza is...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 3 days agoParticipants were administered either a 10μg dose of mRNA-1283 or a 50μg dose of Spikevax. In March...